Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Eden vs Florida Weight Loss MD

Two GLP-1 desks, one scoreboard. We put Eden and Florida Weight Loss MD head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 3 · Grade A−

Eden

Visit Eden Full brief →
vs
No. 322 · Grade C

Florida Weight Loss MD

Visit Florida Weight Loss MD Full brief →

The verdict

Eden takes this head-to-head.

Eden scores 91 to 60 on our six-factor Brief Score — A polished, high-disclosure program with strong nationwide coverage — you pay more, but you know exactly what you're paying for.

That doesn't make Florida Weight Loss MD a bad call — it's best for readers who want florida residents wanting physician-led glp-1 care with an insurance or self-pay option. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
89
36
Supply Reliability
92
73
Transparency
93
68
Access Breadth
90
42
Clinical Oversight
92
78
Track Record
89
70
EdenBrief Score 91 · 60Florida Weight Loss MD

Price, coverage & the tracker

EdenFlorida Weight Loss MD
Brief Score91/100 (A−)60/100 (C)
Semaglutide$239/moNot disclosed
Tirzepatide$349/moNot disclosed
CoverageAll 50 states1 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

Eden: Premium line steady; high supply-chain disclosure keeps our confidence high.

Florida Weight Loss MD: New to the tracker on 1 August 2026. The published line reads From $179/mo (compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.